This is the authors' abstract. We don't add key points for this paper.
Dear Editor, We read with great interest the article by Bageta et al.1 recently published in Clinical and Experimental Dermatology. The authors described three cases of children with epidermolysis bullosa acquisita (EBA) treated with good results with dapsone, oral and topical corticosteroids, and azathioprine. In addition to these treatments, the authors discussed other options such as methotrexate, ciclosporin, cyclophosphamide and rituximab.1 We agree with the authors that the use of corticosteroids followed by steroid‐sparing agents can lead to a favourable outcome for patients with EBA. Current therapeutic options for EBA were described by Bageta et al.1 However, new potential therapeutic targets have also been described in the literature, owing to the increasing understanding of the pathogenesis of EBA. These potential targets interfere at different stages of disease progression, including autoantibody generation, maintenance of circulating autoantibodies and autoantibody‐induced tissue damage. The potential treatment options include new immunobiological targets that can inhibit activation of the complement system (anti‐FcRγ fraction receptors); proteins that decrease the expression of proinflammatory interleukins (IL), such as IL‐6, and stimulate the synthesis of anti‐inflammatory cytokines such as IL‐4 and IL‐10; and molecules and pathways that reduce chemotaxis and neutrophil activation (leukotriene B4, p38 mitogen‐activating protein kinase, granulocyte–macrophage colony‐stimulating factor).2,3 The limitation of these studies relates to the efficacy observed in vivo in experimental animal models for treatment‐refractory EBA and related autoantibody‐mediated diseases. This reported efficacy suggests that introduction of these new compounds would be beneficial, although safety and efficacy profiles for humans must first be confirmed. We believe that the association between EBA and bullous pemphigoid4 may direct future research to identify safe and effective drug targets that can improve the quality of life of these patients. Regarding hereditary forms of epidermolysis bullosa, particularly the recessive dystrophic forms, there are encouraging albeit preliminary new data in the literature, but these are reflected in various case reports on the use of dupilumab as a possible treatment.5,6 Other case reports of recessive dystrophic bullous epidermolysis have been treated with losartan with good results, but further studies are needed to confirm these data.7 In conclusion, rare diseases involve very complex management. Currently, treatments are often unsatisfactory and require a multidisciplinary approach in the management of patients.8,9 Further studies are needed to find new therapeutic targets for these pathologies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Martora et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: